Comparative effects of cyclophosphamide, isophosphamide, 4-methylcyclophosphamide, and phosphoramide mustard on murine hematopoietic and immunocompetent cells
- PMID: 285298
Comparative effects of cyclophosphamide, isophosphamide, 4-methylcyclophosphamide, and phosphoramide mustard on murine hematopoietic and immunocompetent cells
Abstract
The effects of equimolal doses of cyclophosphamide (CY), isophosphamide (IP), 4-methylcyclophosphamide (4-MCY), and phosphoramide mustard (PM) on murine hematopoietic spleen colonies and adoptively transferred antibody-forming cells in vivo were compared. Equimolal doses of the drugs produced significantly different effects. All the drugs exerted an increasing effect against the ability of adoptively transferred immunocompetent cells to produce a significant anti-sheep red blood cell titer as the length of time between cell transfer and drug administration was increased. The maximum effect was seen when a drug was given 48--72 hours after antigen and spleen cell transfer. CY and IP produced significantly greater immunosuppressive effects than did the other drugs at all times after cell transfer and at all doses administered. PM had the least immunosuppressive effect at each dose evaluated. Against hematopoietic spleen colonies, the cytotoxic effects of 4-MCY and PM were similar and, at most doses studied, significantly greater than the effect of either CY or IP. Inasmuch as PM is an active metabolite of CY, it appeared either that one of the prior metabolites of CY was responsible for this marked immunosuppressive effect or that due to differences in polarity, PM was differentially distributed within the two cell systems as compared to CY. The differences in hematopoietic effects among all drugs were much less than those seen against immunocompetent cells and were not dependent on time of drug administration.
Similar articles
-
Enhancement of in vivo and in vitro murine immune responses by the cyclophosphamide metabolite acrolein.Cancer Res. 1988 Jan 1;48(1):41-5. Cancer Res. 1988. PMID: 3257162
-
Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.Cancer Res. 1993 Jun 1;53(11):2490-7. Cancer Res. 1993. PMID: 8495410
-
Vomiting induced by cyclophosphamide and phosphoramide mustard in cats.Cancer Treat Rep. 1982 Aug;66(8):1625-9. Cancer Treat Rep. 1982. PMID: 7105052
-
Metabolism of oxazaphosphorines.Pharmacol Ther. 1988;37(3):301-55. doi: 10.1016/0163-7258(88)90004-6. Pharmacol Ther. 1988. PMID: 3290910 Review. No abstract available.
-
Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses.J Am Acad Dermatol. 1984 Dec;11(6):1115-26. doi: 10.1016/s0190-9622(84)80193-0. J Am Acad Dermatol. 1984. PMID: 6392368 Review.
Cited by
-
Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.Eur J Clin Pharmacol. 1981;19(6):443-51. doi: 10.1007/BF00548589. Eur J Clin Pharmacol. 1981. PMID: 7250178
-
Subtractive immunization yields monoclonal antibodies that specifically inhibit metastasis.J Cell Biol. 1993 Sep;122(6):1351-9. doi: 10.1083/jcb.122.6.1351. J Cell Biol. 1993. PMID: 8376467 Free PMC article.
-
Clinical pharmacokinetics of cyclophosphamide.Clin Pharmacokinet. 1979 Sep-Oct;4(5):380-94. doi: 10.2165/00003088-197904050-00004. Clin Pharmacokinet. 1979. PMID: 389529 Review. No abstract available.
-
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs.Mol Ther Nucleic Acids. 2013 Aug 6;2(8):e113. doi: 10.1038/mtna.2013.38. Mol Ther Nucleic Acids. 2013. PMID: 23922029 Free PMC article.
-
The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.Br J Clin Pharmacol. 1980 Oct;10(4):327-35. doi: 10.1111/j.1365-2125.1980.tb01768.x. Br J Clin Pharmacol. 1980. PMID: 7448105 Free PMC article.